Megakaryon

Executive Summary

Megakaryon is pioneering the development of off-the-shelf platelet products derived from induced pluripotent stem cells (iPSCs), addressing critical shortages and complications in transfusion medicine. By leveraging HLA-homozygous donor iPSCs, the company's technology enables mass production of universal platelets that minimize immune rejection, a major hurdle in current platelet transfusions. The company's lead candidate is currently in Phase 1 clinical trials, evaluating safety and preliminary efficacy in patients. Located in Tokyo, Japan, Megakaryon has raised ¥2.8 billion in funding and operates in the regenerative medicine and hematology space, targeting a significant unmet need in global blood supply. If successful, their platform could revolutionize platelet availability, reduce dependence on donors, and improve patient outcomes in settings such as chemotherapy, trauma, and surgery.

Upcoming Catalysts (preview)

• Q4 2026Readout of Phase 1 clinical trial safety and efficacy data70% success
• Q2 2027Regulatory designation from PMDA (e.g., SAKIGAKE or orphan drug status)60% success
• Q3 2026Strategic partnership with a major pharmaceutical or blood bank organization50% success